Bio-Techne Corporation

Informe acción NasdaqGS:TECH

Capitalización de mercado: US$12.1b

Bio-Techne Dirección

Dirección controles de criterios 3/4

El CEO de Bio-Techne's es Kim Kelderman , nombrado en Feb 2024, tiene una permanencia de menos de un año. compensación anual total es $2.61M, compuesta por 22.6% salario y 77.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.023% de las acciones de la empresa, por valor de $2.25M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 7.3 años, respectivamente.

Información clave

Kim Kelderman

Chief Executive Officer (CEO)

US$2.6m

Compensación total

Porcentaje del salario del CEO22.6%
Permanencia del CEOless than a year
Participación del CEO0.02%
Permanencia media de la dirección1.8yrs
Promedio de permanencia en la Junta Directiva7.3yrs

Actualizaciones recientes de la dirección

Recent updates

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Apr 30
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Apr 15
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30
Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Dec 05
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Oct 10
Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Sep 22
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Sep 01
A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jul 10
At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Jun 22
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Jun 07
With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

May 23
Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Apr 05
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Mar 21
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Mar 06
Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jan 03
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Dec 15
We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Nov 30
Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Nov 17
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne releases new AVV viral titer assays

Oct 11

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Sep 26
At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Sep 12
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Aug 29
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Bio-Techne releases Quantist Luminex data analysis software

Aug 18

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Aug 16
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Teche announces transition plan for CEO Kummeth

Aug 04

Bio-Techne: Resiliency Comes At A Large Premium

Jul 29

Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer

Jul 06

Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?

Jun 22
Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?

Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?

Jun 09
Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

May 26
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kim Kelderman en comparación con los beneficios de Bio-Techne?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

US$203m

Dec 31 2023n/an/a

US$224m

Sep 30 2023n/an/a

US$247m

Jun 30 2023US$3mUS$590k

US$285m

Mar 31 2023n/an/a

US$271m

Dec 31 2022n/an/a

US$262m

Sep 30 2022n/an/a

US$292m

Jun 30 2022US$3mUS$562k

US$272m

Mar 31 2022n/an/a

US$225m

Dec 31 2021n/an/a

US$210m

Sep 30 2021n/an/a

US$177m

Jun 30 2021US$4mUS$530k

US$140m

Mar 31 2021n/an/a

US$184m

Dec 31 2020n/an/a

US$175m

Sep 30 2020n/an/a

US$248m

Jun 30 2020US$2mUS$500k

US$229m

Mar 31 2020n/an/a

US$187m

Dec 31 2019n/an/a

US$195m

Sep 30 2019n/an/a

US$93m

Jun 30 2019US$2mUS$452k

US$96m

Mar 31 2019n/an/a

US$121m

Dec 31 2018n/an/a

US$96m

Sep 30 2018n/an/a

US$128m

Jun 30 2018US$2mUS$73k

US$126m

Compensación vs. Mercado: La compensación total de Kim($USD2.61M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Kim ha sido consistente con los resultados de la empresa en el último año.


CEO

Kim Kelderman (55 yo)

less than a year

Permanencia

US$2,605,712

Compensación

Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Kim Kelderman
CEO, President & Directorless than a yearUS$2.61m0.023%
$ 2.7m
James Hippel
Executive VP of Finance & CFO10.1yrsUS$3.44m0.046%
$ 5.6m
Shane Bohnen
Senior VP1.2yrsUS$1.04m0.0010%
$ 127.6k
Charles Kummeth
Senior Advisorless than a yearUS$30.58m0.81%
$ 98.8m
William Geist
President of Protein Sciences Segment2.3yrsUS$2.33m0.0028%
$ 342.6k
Gary Latham
VP & CTOless than a yearsin datossin datos
David Clair
Senior Director of Investor Relations & Corporate Developmentno datasin datossin datos
Gerry Andros
Vice President of Sales and Marketingno datasin datossin datos
Robert Gavin
Vice President of Corporate Development3.3yrsUS$1.37msin datos
Luca Cicchetti
Managing Director7.8yrssin datossin datos
Kevin Smyth
Senior VP & Chief Digital Officer6.3yrssin datossin datos
Steve Crouse
Senior Vice President of Analytical Solutions Division1.3yrssin datossin datos

1.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TECH no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Kim Kelderman
CEO, President & Directorless than a yearUS$2.61m0.023%
$ 2.7m
Robert Baumgartner
Independent Chairman of the Board21.3yrsUS$410.30k0.028%
$ 3.4m
John Higgins
Independent Director15yrsUS$300.30k0.023%
$ 2.8m
Joseph Keegan
Independent Director7.3yrsUS$275.30k0.0078%
$ 951.3k
Randolph Steer
Independent Director34.3yrsUS$285.51k0.015%
$ 1.9m
Roeland Nusse
Independent Director14yrsUS$290.30k0.027%
$ 3.3m
Julie Bushman
Independent Director3.8yrsUS$282.59k0.0036%
$ 438.6k
John Denu
Member of Scientific Advisory Boardno datasin datossin datos
Sachdev Sidhu
Member of Scientific Advisory Boardno datasin datossin datos
S. J. Vessey
Independent Director4.9yrsUS$275.30k0.0050%
$ 609.9k
Alpna Seth
Independent Director7.3yrsUS$275.30k0.0078%
$ 951.3k
David Artis
Member of Scientific Advisory Boardno datasin datossin datos

7.3yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de TECH se considera experimentada (7.3 años de antigüedad promedio).